Table 4.
OLS regression on TSQM global satisfaction domain scores (n=46)
| Independent variable | Estimate (SE) | 95% CI | P-value |
|---|---|---|---|
| Initial model (R-squared =0.59) | |||
| TSQM effectiveness score | 0.76 (0.16) | 0.45, 1.06 | <0.001 |
| TSQM side-effects score | 0.21 (0.14) | −0.06, 0.48 | 0.119 |
| TSQM convenience score | −0.08 (0.14) | −0.34, 0.19 | 0.561 |
| Patient sex (0= female, 1= male) | 4.94 (4.93) | −4.73, 14.61 | 0.317 |
| Patient age | −1.35 (1.01) | −3.34, 0.64 | 0.183 |
| Squared patient age | 0.02 (0.02) | −0.02, 0.05 | 0.284 |
| Work/school statusa | −1.87 (4.91) | −11.50, 7.76 | 0.704 |
| Education levelb | 7.49 (4.47) | −1.27, 16.25 | 0.094 |
| FEV1 | −0.15 (0.09) | −0.33, 0.03 | 0.108 |
| BMI | 0.46 (0.79) | −1.09, 2.01 | 0.561 |
| CFQ-R respiratory score | −0.06 (0.18) | −0.41, 0.30 | 0.750 |
| CFQ-R health perception score | 0.15 (0.14) | −0.12, 0.42 | 0.281 |
| CFQ-R treatment burden score | 0.03 (0.12) | −0.20, 0.26 | 0.803 |
| Number of TIP cycles completedc | −0.71 (4.25) | −9.05, 7.62 | 0.867 |
| Intercept | 13.57 (24.98) | −35.40, 62.53 | 0.587 |
| Final model following stepwise elimination (R-squared =0.54) | |||
| TSQM effectiveness score | 0.75 (0.12) | 0.52, 0.98 | <0.001 |
| TSQM side effects score | 0.23 (0.12) | −0.02, 0.47 | 0.069 |
| Education levelb | 5.77 (4.03) | −2.12, 13.67 | 0.152 |
| Intercept | −4.14 (13.40) | −30.41, 22.13 | 0.757 |
Notes:
a
Asked of parent or caregiver for children 6–13 years old; 0= not currently working/at school, 1= currently working/at school;
b
Asked of parent or caregiver for children 6–13 years old; 0= less than college education, 1= some college education or higher;
c
0=4 or more cycles, 1=3 or fewer cycles.
Abbreviations: BMI, body mass index; CFQ-R, Cystic Fibrosis Questionnaire-Revised; CI, confidence interval; FEV1, forced expiratory volume in 1 second; OLS, ordinary least squares; SE, standard error; TSQM, Treatment Satisfaction Questionnaire for Medication; TIP, tobramycin inhalation powder.